{
    "2019-05-09": [
        [
            {
                "time": "",
                "original_text": "上海新世纪资信评估维持复星医药(600196)主体及债项AAA信用等级，展望稳定。",
                "features": {
                    "keywords": [
                        "复星医药",
                        "信用等级",
                        "AAA",
                        "展望稳定"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "2018年中国医药健康产业上市企业创新能力TOP100",
                "features": {
                    "keywords": [
                        "2018年",
                        "医药健康",
                        "创新能力",
                        "TOP100"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "港股异动丨医药板块普跌 中生物制药跌逾4%",
                "features": {
                    "keywords": [
                        "港股",
                        "医药板块",
                        "普跌",
                        "中生物制药",
                        "跌逾4%"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "2018年A股药企研发投入概况回顾",
                "features": {
                    "keywords": [
                        "2018年",
                        "A股",
                        "药企",
                        "研发投入",
                        "回顾"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药板块估值重塑 性价比优势凸显 六股值得关注",
                "features": {
                    "keywords": [
                        "医药板块",
                        "估值重塑",
                        "性价比",
                        "六股",
                        "关注"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}